Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development, and commercialization of drugs and diagnostic products for the aging population in the United States, Canada, Europe, and other countries. It provides AlzheimAlert, a urinary test that helps physicians in the diagnosis of Alzheimer's disease; and NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. The company's products under development include NX-1207, which in Phase III clinical trials for the treatment of benign prostatic hyperplasia, as well as in human clinical trials to treat hepatocellular carcinoma and localized prostate cancer; and NXC-4720, an antibacterial agent for the treatment of E. coli O157:H7 bacterial contamination in hamburger meat and other food and drink products, and for the treatment of urinary tract and other bacterial infections in humans. Its products under development also comprise NXB-4221 for the treatment of chronic and persistent urinary tract infections; NXB-5886 for the treatment of streptococcal infection; and NXT-1021 for the treatment of staphylococcal infection. In addition, the company is involved in the research and development of drugs at various treatments for Alzheimer's disease and other indications; drugs for the treatment of Alzheimer's disease that targets spherons; and neural thread protein-based drugs, as well as developing various therapeutic products that are in the preclinical stage for oncology indications. It has license and collaboration agreement with Recordati Ireland Ltd. for the development and commercialization of NX-1207. The company was founded in 1989 and is headquartered in Saint Laurent, Canada.
